Welcome to Helix Talk, a podcast presented by the Rosalind Franklin University College of Pharmacy.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge. This podcast contains general information for educational purposes only. This is not

professional advice and should not be used in lieu of obtaining advice from a qualified health care

provider. And now, on to the show. Welcome to Helix Talk episode 33. I'm her co-host, Dr. Kane.

I'm Dr. Schumann. And I'm Dr. Patel. And this week we're talking about a newly approved drug and drug class called the PCSK-9 inhibitors

with a particular focus on the one that was first approved by the FDA recently.

So that agent is marketed as brand name of preluent, and generic is Allerocomab, and this was approved

by FDA in July 2015.

Another agent of the similar category is out, Ibelocomab or Rapatha, and that one is approved

in August 2015.

So normally when I think about newly approved drug therapy, generally speaking,

some of the new drugs that make it to the market aren't really game changers, if you will.

So if you go back a couple episodes, we talked about kind of some of the drugs of drug classes

over the past 20 years that we really felt like we're game changers.

And I could view this as a potential game changer, this new drug class that we're talking about

today.

Yeah, let's see.

Let's look into more of the clinical trials, the evidence behind them, and see if you can

really call it a game changer.

And it certainly, I believe, has some of the way it's come about.

It fits into some of that game changer kind of criteria.

...